17 results about "Disintegrin" patented technology

The invention relates to the technical field of medicines, and provides application of pulsatilla saponin B4 in preparation of a medicine for treating osteoarthritis. The pulsatilla saponin B4 can obviously promote the expression of SOX9, which is an important cartilage specific transcription factor, and inhibit the expression of matrix metalloproteinase 13 and disintegrin and metalloproteinase 5 with platelet reaction protein motifs at the same time, thereby finally relieving the degradation of extracellular cartilage matrixes such as II-type collagen and aggregation proteoglycan. Therefore, the pulsatilla saponin B4 can inhibit cartilage degeneration and improve cartilage extracellular matrix metabolic disorder. After the pulsatilla saponin B4 is injected into the abdominal cavity of a mouse with osteoarthritis, the progress of the osteoarthritis is effectively relieved, the side effect is relatively small, and no obvious injury is caused to main organs. The pulsatilla saponin B4 is applied to treatment of osteoarthritis, new application of the pulsatilla saponin B4 is developed, and a new choice is provided for preparation of the medicine for treating osteoarthritis.

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The present invention relates to the use of ADAMTS12 protein, a disintegrin and metalloproteinase 12 protein having a platelet-reactive protein motif, in the development of chronic kidney diseases, in particular progressive chronic kidney diseases and renal fibrosis. In particular, the present invention relates to a method for identifying compounds that bind to ADAMTS12 protein and the use of ADAMTS12 protein for screening and identifying ADAMTS12 interacting compounds and ADAMTS12 inhibiting compounds. The present invention also relates to pharmaceutical compositions for the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit ADAMTS12 protein (Fig. 5).

Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.

The invention provides methods for treating conditions of immune disfunction, such as rheumatoid arthritis (RA), using enzyme- and substrate-selective exosite inhibitors of A disintegrin and metalloprotease 10 (ADAM10), such as N-(3-chloro-4-methylphenyl)-2-[2-(3-methoxybenzoyl) hydrazinyl]-2-oxoacetamide (PubChem CID3117694). The method for treating a condition of immune disfunction in a subject in need thereof includes: providing a composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10) and at least one acceptable pharmaceutical carrier; and administering the composition to the subject, thereby treating the condition of immune disfunction in the subject by modulating ADAM10. A composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10), a therapeutically effective dosage of indomethacin, and at least one acceptable pharmaceutical carrier is for use in treating a condition of immune disfunction or inflammation in a subject in need thereof.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (A disintegrin and metalloproteinase with thrombospondin motifs 12-protein) in the pathogenesis of chronic kidney and heart diseases and in particular chronic renal insufficiency and renal fibrosis or cardiac insufficiency and cardiac fibrosis. The present invention relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, and to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active ingredients that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The disclosure provides a method for treating and / or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMT S13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.

A method comprising administering, to a subject in need thereof, an effective amount of a nucleotide effective to disrupt one or more pathways leading to sepsis. The nucleotide may be a nitric oxide disruptor effective to decrease the expression of inducible nitric oxide synthase. The nitric oxide disrupter may comprise a polynucleotide strand exhibiting at least 70% sequence identity to one of Sequence ID No. 1 through Sequence ID No. 47. Additionally or alternatively, the nucleotide may be an α disintegrin and metalloproteinase (ADAM) enzyme inhibitor effective to decrease the expression of ADAM enzyme. The ADAM enzyme inhibitor may comprise a polynucleotide strand exhibiting at least 70% sequence identity to one of Sequence ID No. 48 through Sequence ID No. 56.

The present invention relates to the role of ADAMTS12 protein (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 12 protein) in the development of chronic kidney disease, in particular progressive chronic kidney disease and renal fibrosis. In particular, the present invention relates to methods for identifying compounds that bind to the ADAMTS12 protein and to the use of ADAMTS12 protein for screening and identifying ADAMTS12-interacting and ADAMTS12-inhibiting compounds. The present invention further relates to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit the ADAMTS12 protein.

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The application relates to the field of biological medicine, in particular to a detection method and application of ophidiotoxin and vivero toad venom. (1) Antibodies obtained by immunizing a mixture of SVSP chimeras and Disintegrin chimeras and two kinds of antigens of 3FT chimeras can effectively identify ophidiotoxin and vivero toad venom; (2) Antibodies obtained by immunizing two kinds of antigens of multicinctus 3FT chimeras and Atra 3FT chimeras can effectively identify ophidiotoxin and silver ring snake venom; (3) The cation exchange chromatography method is used to enrich the snake venom in the sample, and the sensitivity of the to-be-detected snake venom in blood and tissue fluid is improved; (4) Standard samples of cobra and silver ring snake venom are established for the first time. Compared with the prior art, the method has the effects of identifying vivero toad venom and ophidiotoxin by searching for difference proteins, predicting linear antigen epitopes, removing the same and highly similar linear antigen epitopes and serially recombinantly expressing the linear antigen epitopes.

To provide: multi-specific binding proteins that bind the Natural killer group 2 member D (NKG2D), cluster of differentiation 16 (CD16), and a tumor-associated antigen; and pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.SOLUTION: A protein comprises: (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds an antigen selected from the group consisting of EpCAM, Cancer Antigen 125, sodium / phosphate cotransporter 2B, Nectin cell adhesion molecule 4, Fucosyl-GM1, disintegrin and metalloproteinase domain-containing protein 8, disintegrin and metalloproteinase domain-containing protein 9, solute carrier family 44 member 4, and sialylated Lewis a antigen; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.SELECTED DRAWING: None

The present disclosure provides compositions and methods for treating, ameliorating and / or preventing vaso-occlusive crises (VOCs) in subjects with sickle cell disease (SCD). The present disclosure also provides compositions and methods for treating, ameliorating and / or preventing lung injury in subjects with acute lung injury (ALI) and / or acute respiratory distress syndrome (ARDS) or at risk of developing acute lung injury (ALI) and / or acute respiratory distress syndrome (ARDS). The present disclosure provides a disintegrin-like metalloproteinase 13 (ADAMTS13) containing a type I thrombobinding protein motif or a composition comprising ADAMTS13 for treating, ameliorating and / or preventing VOCs, or for treating, ameliorating and / or preventing lung injury in subjects with ALI and / or ARDS or at risk of developing ALI and / or ARDS.

The disclosure relates to a method of treating cancer in a subject, the method comprising administering (a) a wild-type Staphylococcus aureus alpha hemolysin (Hla) polypeptide or a fragment thereof; or (b) a Staphylococcus aureus biofilm-conditioned medium (BCM) or a purified fraction thereof comprising a wild-type Staphylococcus aureus Hla polypeptide to the subject, wherein the cancer expresses a disintegrin and metalloprotease 10 (ADAM10). Also disclosed is a method of preparing Staphylococcus aureus BCM comprising culturing Staphylococcus aureus within a wool scaffold, such as aquaria filter wool, in a culture media.

Methods for treating conditions of immune disfunction, such as rheumatoid arthritis (RA), use enzyme- and substrate-selective exosite inhibitors of A disintegrin and metalloprotease 10 (ADAM10), such as N-(3-chloro-4-methylphenyl)-2-[2-(3-methoxybenzoyl) hydrazinyl]-2-oxoacetamide (PubChem CID3117694). The method for treating a condition of immune disfunction in a subject in need thereof includes: providing a composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10) and at least one acceptable pharmaceutical carrier; and administering the composition to the subject, thereby treating the condition of immune disfunction in the subject by modulating ADAM10. A composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10), a therapeutically effective dosage of indomethacin, and at least one acceptable pharmaceutical carrier is for use in treating a condition of immune disfunction or inflammation in a subject in need thereof.